Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Jul;2(4):253-8.
doi: 10.1007/BF00365732.

Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases

Affiliations
Free article

Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases

A Moran-Ribon et al. Support Care Cancer. 1994 Jul.
Free article

Abstract

Among patients suffering from nonseminomatous germ-cell tumor, with a poor prognosis, a subset underwent respiratory failure and died very early in the course of their treatment. Between 1982 and 1989, 11 out of 56 such patients (20%) died within the first 5 weeks of chemotherapy. The clinical, radiological, biological and infectious characteristics of these patients were analyzed. Nine patients had extensive pulmonary metastases and the 2 others presented a bulky mediastinal mass with pleural effusion. All patients experienced acute respiratory distress during chemotherapy and underwent mechanical ventilation. All patients were febrile, and septicemia was documented in 7 cases. WHO grade 4 and grade 1-2 renal toxicities occurred in 3 and 4 patients respectively. There was no tumor lysis syndrome. All patients died within 35 days from the start of therapy; 4 were autopsied. These 11 patients represent a clinical entity, having what we called super-high-risk germ cell tumors. Early death is related to pulmonary distress within the first 5 weeks of therapy. The origin of the pulmonary distress is multifactorial: bulky disease of the chest, infection, and interstitial fibrosis. Immediate full-dose standard chemotherapy in association with intensive supportive care is recommended in the management of these patients.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Oncol. 1990 Nov;8(11):1777-81 - PubMed
    1. Support Care Cancer. 1994 Mar;2(2):128-31 - PubMed
    1. Br J Urol. 1986 Jun;58(3):307-14 - PubMed
    1. Bull Cancer. 1992;79(5):497-507 - PubMed
    1. J Clin Oncol. 1988 Aug;6(8):1231-8 - PubMed

MeSH terms

LinkOut - more resources